Mastek Q1 FY27: Growth Returns, AI Deal Momentum Builds, Middle East Weighs on Margins

Mastek reported a steadier start to FY27, with revenue from operations of ₹985.3 crore in Q1 FY27, up 7.7 percent year-on-year and 5.0 percent quarter-on-quarter. Operating EBITDA came in at ₹151.4 crore, translating to a 15.4 percent margin, while PAT was ₹105.9 crore at a 10.6 percent margin.

The quarter’s core narrative was the company’s shift toward being an AI engineering and transformation partner. Management said it closed 40 plus new AI deals in Q1 FY27 and that around 45 percent of new order booking came from AI deals. At the same time, profitability softened sequentially, with management attributing the margin decline mainly to delayed collections and higher bench cost in the Middle East.

What drove the quarter: UK and Europe strength, US momentum, AMEA disruption

By market region, UK and Europe remained dominant at 67.3 percent of revenue in Q1 FY27, up from 66.4 percent in Q4 FY26. The US contributed 21.7 percent, broadly stable, and AMEA slipped to 11.0 percent.

Management commentary pointed to steady demand in the UK public sector and a positive private sector environment shaped by AI-led initiatives. In healthcare, the company flagged a near-term transition in the UK business as older projects ramped down and new data modernization projects started, creating a timing gap that also influenced concentration metrics.

North America was positioned as improving on order booking, led by a $25 million AI transformation deal on Salesforce Agentforce. However, management said the ramp-up for that specific large deal is expected by H2 FY27.

AMEA remained the operational drag. Management highlighted geopolitical uncertainty in the Middle East as a reason for business unpredictability, slower ramp-ups, and delayed collections that affected EBITDA.

Financial summary (Consolidated)

Mix trends: public sector scale and a growing AI and data line

Industry-wise, Government and Education remained the largest segment at 42.9 percent of Q1 FY27 revenue, followed by Health and Life Sciences at 19.3 percent and Financial Services at 15.0 percent. The mix indicates that Mastek’s revenue base continues to be shaped by large public sector and healthcare programs, with financial services showing improvement in management commentary through UK banking wins such as FCA.

Service lines also show a portfolio that still leans heavily on core engineering and enterprise applications. Digital and Application Engineering contributed 50.0 percent of revenue, and Oracle Cloud and Enterprise Apps accounted for 27.2 percent. Data, Automation and AI stood at 13.4 percent. On the concall, the CFO noted that the data, automation and AI business grew 9.8 percent sequentially, reinforcing the company’s stated AI transformation direction.

Contract type mix moved slightly toward fixed price, with fixed price contracts at 43.1 percent in Q1 FY27 versus 42.7 percent in Q4 FY26. This matters because management also discussed pricing pressure and aggressive competition. In the concall, management acknowledged renewal discounts typically around 15 percent and up to 20 to 25 percent in a few cases, while stating that fixed bid and outcome-based delivery could still support margin outcomes if executed with higher productivity.

Cash, collections, and operating discipline amid volatility

Despite margin pressure, the balance sheet and cash position improved. Cash, cash equivalents and investments were ₹945.4 crore at the end of Q1 FY27. The company stated that its net cash and investment position improved by around ₹200 crore over the last two quarters.

Collections were highlighted as strong, but the quarter still saw working-capital friction. DSO increased to 75 days from 73 days in Q4 FY26, with management attributing part of the increase to a $2.5 million collection that shifted into the first days of July and the geopolitical headwinds in AMEA.

Operationally, headcount rose to 4,897 employees, up 167 in the quarter. Attrition improved to 16.4 percent on a last-twelve-month basis, compared to 17.4 percent in Q4 FY26. Utilization net of leave fell to 83.9 percent from 85.7 percent, with management linking it to order pushouts and Middle East disruptions.

The company also disclosed an income tax assessment for FY 2022-23 that added income of ₹91 crore on transfer pricing and ₹32.5 crore on domestic tax matters, with an estimated tax impact of approximately ₹31 crore. Management stated an appeal was filed.

The takeaway: AI-led bookings are rising, but conversion and regional risk matter

Q1 FY27 reinforced a clearer strategic positioning around AI-led transformation. The company’s narrative is supported by reported AI deal volume, showcased case studies, and a stated shift toward AI-native delivery methods such as ADOPT AI and agentic AI managed services.

However, the quarter also showed what can disrupt that story in the near term. AMEA volatility affected collections and margins, utilization moved down, and competitive pricing remains a factor across renewals and new wins. Management did not provide formal guidance, but did state that FY27 performance should be better than FY26, and that the large North America deal ramp-up is expected by H2 FY27.

For investors, the next few quarters will likely hinge on how quickly AI-led order booking converts into billed revenue, whether UK healthcare transitions normalize from Q2, and whether Middle East collections and delivery predictability stabilize enough to protect margins.